1. A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study. (November 2022) Authors: Miglietta, F.; Ragazzi, M.; Fernandes, B.; Griguolo, G.; Massa, D.; Bisagni, A.; Bottosso, M.; Porra, F.; Gaudio, M.; Iannaccone, D.; Fassan, M.; Lo Mele, M.; Gasparini, E.; Zarrilli, G.; Coiro, S.; Dore, L.; Zambelli, A.; Bisagni, G.; Guarneri, V.; Dieci, M.V. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The relationship among bowel FDG-PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy. (November 2022) Authors: Tiberio, P.; Antunovic, L.; Gaudio, M.; Viganò, A.; Pastore, M.; Miggiano, C.; Jacobs, F.; Benvenuti, C.; Farina, E.; Chiti, A.; Santoro, A.; De Sanctis, R. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗